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EKSPRESI, PENULENAN DAN PENCIRIAN KOLINA KINASE PUTATIF 
DARIPADA MIKROORGANISMA 
ABSTRAK 
Kerintangan antimikrob (AMR) telah menjadi suatu ancaman kepada komuniti 
seluruh dunia. AMR dijangka akan mengakibatkan sepuluh juta kematian setahun 
menjelang 2050. Dalam bakteria, kolina kinase (ChoK) bertanggungjawab untuk 
mensintesis fosforilkolina, iaitu prekursor kepada asid lipoteikoik dan asid teikoik 
dinding sel pada bakteria Gram positif. Dalam bakteria Gram negatif, fosforilkolina 
digabungkan ke dalam lipopolisakarida membran yang mengawalatur interaksi 
patogen dan sel hos. Perencat kolina kinase (ChoKIs) yang merosakkan dinding sel 
telah diuji pada Streptococcus pneumoniae dan menunjukkan keputusan yang 
memberangsangkan. Aktiviti ChoKIs juga boleh ditingkatkan dengan menggunakan 
partikel nano yang berfungsi sebagai sistem penghantaran ubat. Penghasilan sasaran 
ubat (iaitu ChoKs daripada bakteria) dalam bentuk protein rekombinan adalah penting 
untuk menguji keberkesanan ChoKIs. Kajian ini cuba menangani isu AMR dengan 
meneroka keadaan terbaik untuk penghasilan ChoKs rekombinan daripada 
Staphylococcus aureus (SaChoK), Neisseria meningitidis (NiChoK) dan Haemophilus 
influenzae (HiChoK) diikuti dengan penilaian in silico ketiga-tiga ChoKs ini sebagai 
sasaran berpotensi untuk ChoKIs menggunakan kaedah pemodelan struktur dan 
pelabuhan molekul. Ketiga-tiga ChoKs bakteria pada asalnya diklonkan dalam vektor 
pET14b untuk ekspresi sebagai protein bertanda His. Walau bagaimana pun, ramalan 
bioinformatik kelarutan protein menunjukkan bahawa kelarutan ChoKs bertanda His 
adalah kurang daripada kelarutan purata protein E. coli terlarut. Ekspresi protein pada 
periplasma menggunakan plasmid pGEX telah ditunjukkan dapat meningkatkan 
kelarutan protein. Oleh itu, gen SaChoK telah disubklonkan daripada pET14b-
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SaChoK ke dalam vektor pGEX. Berdasarkan ramalan in silico, SaChoK, NmChoK 
dan HiChoK bertanda GST akan lebih terlarut dan dapat dihasilkan dalam kuantiti 
yang lebih tinggi berbanding protein bertanda His yang dihasilkan daripada vektor 
pET14b. Pelabuhan molekul untuk struktur model SaChoK, NmChoK dan HiChoK 
dengan Hemicholinium-3 (HC-3), suatu ChoKI molekul kecil yang terbukti kesannya, 
telah menunjukkan mod perlekatan sempurna pada poket perlekatan kolina dan 
menyokong kemungkinan perencatan kompetitif oleh HC-3. Pertindanan tiga struktur 
model ChoK bakteria berkenaan dengan ChoK manusia menyerlahkan homologi yang 
ketara dan seterusnya menyokong penggunaan ChoKIs yang telah digunakan ke atas 
ChoK manusia untuk merencat bakteria AMR. Penghasilan pGEX-SaChoK dan 
ramalan bioinformatik telah membuka jalan kepada ekspresi secara optimum SaChoK, 
NmChoK dan HiChoK dalam sistem E. coli. Keputusan pelabuhan molekul 
menunjukkan potensi aplikasi ChoKIs untuk menentang AMR. Oleh itu, kajian ini 
telah merintis haluan ke arah ekspresi ChoKs bakteria terlarut untuk diuji dengan 
ChoKIs sedia ada dan meyerlahkan potensi perencat ini sebagai agen antimikrob.  
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EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF 
PUTATIVE CHOLINE KINASES FROM MICROORGANISMS 
ABSTRACT 
Antimicrobial resistance (AMR) has been a menace to communities 
worldwide. AMR is estimated to cause ten million deaths a year by 2050. In bacteria, 
choline kinase (ChoK) is responsible for the synthesis of phosphorylcholine, which is 
a precursor for lipoteichoic acid and cell wall teichoic acid in Gram-positive bacteria. 
In Gram-negative bacteria, phosphorylcholine is incorporated into membrane 
lipopolysaccharides that modulate pathogen-host cell interactions. Choline kinase 
inhibitors (ChoKIs) that deteriorate the bacterial cell wall, have already been tested on 
Streptococcus pneumoniae with great results. ChoKIs activity can be also be enhanced 
by nanoparticles that act as a drug delivery system. The generation of the drug targets 
(bacterial ChoKs) in the form of recombinant proteins, is vital for testing the efficacy 
of ChoKIs. This study will attempt to address the issue of AMR by searching for the 
best conditions for the productions of recombinant ChoKs from Staphylococcus 
aureus (SaChoK), Neisseria meningitidis (NmChoK) and Haemophilus influezae 
(HiChoK) followed by in silico evaluation of these ChoKs as potential targets for 
ChoKIs by structural modeling and molecular docking approach. All three bacterial 
ChoKs were originally cloned in the pET14b vector for overexpression as His-tagged 
proteins. However, bioinformatic protein solubility prediction revealed that the 
solubility propensity of the His-tagged ChoKs tends to be less than the average soluble 
E. coli proteins. The protein overexpression in the periplasm using pGEX plasmid has 
been shown to increase protein solubility. Therefore, the SaChoK gene was subcloned 
from pET14b-SaChoK into a pGEX vector. Based on in silico prediction, the GST-
tagged SaChoK, NmChoK, and HiChoK would be more soluble and produced at higher 
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yields compared to His-tagged proteins produced from the pET14b vector. Molecular 
docking of SaChoK, NmChoK, and HiChoK model structures with Hemicholinium-3 
(HC-3), an established small-molecule ChoKI, exhibited a fit binding mode inside the 
choline-binding pocket, indicating promising competitive inhibition by HC-3. 
Superimpositions of the three bacterial ChoK model structures with human ChoK 
revealed an ample homology, further supporting the use of ChoKIs previously used to 
inhibit human ChoK on AMR bacteria. The production of pGEX-SaChoK and the 
bioinformatic predictions have laid the groundwork for optimal overexpression of 
SaChoK, NmChoK, and HiChoK in E. coli system. The molecular docking results 
demonstrate the promising application of ChoKIs to combat AMR. Therefore, this 
study has paved the way towards successful overexpression of soluble recombinant 
bacterial ChoKs to be tested with currently available ChoKIs and reveal the potential 













The swift adaptation of the bacteria in the revolutionary development of 
antibiotics made it easy for it to develop resistance to the antibiotics. With the halt of 
antibiotic discovery nowadays, there are no guarantees that humanity can manage to 
combat these adapted bacteria. This signals the looming perspective of the return of 
the “pre-antibiotic era” (Jayachandran, 2018). Therefore, a novel solution is needed 
(Draenert et al., 2015; Duval et al., 2019) to balance the scales and combat these 
bacteria, especially in this era, that is designated by the Centers for Disease Control 
and Prevention (CDC) as a ‘‘post-antibiotic era’’ (Gupta et al., 2019). In which the 
discovery of antibiotics has come to a standstill marking the “golden era” of antibiotic 
development as extinct (Davies, 2006; Aminov, 2010). More so, where every known 
antibiotic has been outmaneuvered by the bacteria via developing resistance to it 
(Payne et al., 2007). The stalemate in antibiotic development and the continuous 
antimicrobial resistance (AMR) escalation has led to the emergence of this 
predicament (Coates et al., 2011; Nathan and Cars, 2014). Along with the lack of 
research, the continuous use of the existing antibiotics has greatly stimulated AMR 
nowadays more than ever (Chambers, 2001; Davies and Davies, 2010; Llor and 
Bjerrum, 2014; Wojkowska-Mach et al., 2018). It has even been estimated that AMR 
will cause ten million deaths each year by 2050 (de Kraker et al., 2016; Sugden et al., 
2016; World Health Organization, 2019). Therefore, AMR must be dealt with 
immediately as the Infectious Diseases Society of America (IDSA) has stated 
concerning AMR “one of the greatest threats to human health worldwide” (Infectious 
Diseases Society of America et al., 2011). 
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No bacteria have ever shown a more remarkable adaptive example of AMR 
than Staphylococcus aureus (Figure 1.1). Along with the revolution of the “antibiotic 
era”, came the inauguration of the AMR of S. aureus by first developing it towards 
penicillin after being introduced in the 1940s (Chambers and Deleo, 2009; Hiramatsu 
et al., 2014; Foster, 2017). Particularly from 1942 (Rammelkamp and Maxon, 1942), 
which has proven S. aureus to be a formidable adversary. It has given rise to a 
pandemic by the penicillin-resistant strain known as the phage-type 80/81 (Brodie et 
al., 1956). The strain and the pandemic vanished soon after the inception of methicillin 
in 1960 in uncertain circumstances (DeLeo et al., 2011). Soon after that, the genesis 
of methicillin-resistant S. aureus type I (MRSA-I) has been established until the 1970s 
(Jevons, 1961; Chambers and Deleo, 2009; Foster, 2017). Eventually, MRSA-II and 
III have emerged in the mid to late 1970s, marking the MRSA pandemic, then the 
smaller more mobile MRSA-IV surfaced in the 1990s (Chambers and Deleo, 2009). 
Vancomycin (VAN) has been usually used to treat MRSA, but only as a last-
line treatment and daptomycin (DAP) as well (Barros et al., 2019). Linezolid is now 
applied for MRSA as a clinical alternative for vancomycin (Endimiani et al., 2011). S. 
aureus has stood as the victor yet again by developing AMR towards them. Beginning 
with vancomycin known as vancomycin-intermediate S. aureus (VISA) in the 1990s, 
vancomycin-resistant S. aureus (VRSA) in 2002 (Chambers and Deleo, 2009), and 
daptomycin in 2003 (DAP-R) (Marty et al., 2006). VISA and VRSA are treated with 
daptomycin (Tran et al., 2015) and linezolid (Safa et al., 2016), however, AMR to 
linezolid has also emerged in 2004 (Endimiani et al., 2011). AMR in S. aureus has 
even led to elevated hemolysis with alcohol  (Korem et al., 2007) and biofilms to thrive 









Many bacteria other than S. aureus have shown remarkable resistance to 
antibiotics such as Haemophilus influenzae (Campos, 2001; Nag et al., 2001; Campos 
et al., 2003; Tristram et al., 2007; Yokota et al., 2009; Bae et al., 2010; Kostyanev and 
Sechanova, 2012), Neisseria meningitidis (Oppenheim, 1997; Gorla et al., 2018; 
Vacca et al., 2018; Zouheir et al., 2019), Neisseria gonorrhoeae (Unemo and Shafer, 
2011; Wi et al., 2017; MacFadden et al., 2018; Cristillo et al., 2019; Rubin et al., 2020), 
Streptococcus pneumoniae (Appelbaum et al., 1977; Jacobs, 1999; Kim et al., 2016; 
Cherazard et al., 2017), Streptococcus mitis and Streptococcus oralis (Ono et al., 2000; 
Humphries et al., 2013; Adams et al., 2017; Mishra et al., 2017; van Prehn et al., 2019), 
and Pseudomonas aeruginosa and Klebsiella pneumoniae that are known as 
extensively drug-resistant (XDR) and pandrug-resistant (PDR) (Pontikis et al., 2014; 
Zhi-Wen et al., 2015). AMR is even considered a virulence factor for the bacteria 
(Aslam et al., 2018), where the outcome of infection with multidrug-resistant (MDR) 
bacteria is worse than the susceptible counterpart (Bodi et al., 2001; Vardakas et al., 
2013; van Duin and Paterson, 2016; Perdikouri et al., 2019). Many strategies explain 
that including i) the destruction or inactivation of the antibiotic molecule, ii) reducing 
the antibiotic within the cell via decreased penetration or extracellular expulsion of the 
antibiotic via the manifestation of efflux pumps, iii) structural change of the target site 
via a gene mutation, enzymatic reaction, or swiping the target site with a new 
antibiotic-invincible site (Munita and Arias, 2016). Salmonella enterica can even 
develop AMR upon acquiring mobile genetic elements (Hoffmann et al., 2017; 
Kudirkiene et al., 2018; Sultan et al., 2018). 
These mechanisms of AMR are the reason behind the incredible speed of 
bacterial adaptation towards antibiotics. Even the World Health Organization (WHO) 
has declared AMR as the ‘growing threat’ (World Health Organization, 2014; 
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Lyddiard et al., 2016). The community, however, have played a big part in it as well, 
most notably, self-medication from previously prescribed drugs (Grigoryan et al., 
2007), the administration of antibiotics over the counter in developing countries 
(Zaman et al., 2017), and the inappropriate use of antibiotics by the community and 
health workers alike (Ena et al., 1993; Mehrad et al., 2015; Adedeji, 2016; van Duin 
and Paterson, 2016). To curb this predicament, public awareness has to be increased 
and a novel method needs to be developed. The key perhaps would be the application 
of novel drugs designated for eukaryotic cells with the ability to debilitate prokaryotic 
cells. Nanoparticles (NPs) are yet another key to the puzzle of AMR. Better yet, a 
combination between those two solutions would probably produce highly effective 
antimicrobic, impervious to AMR, even in the future. 
One promising novel antimicrobic is choline kinase inhibitors (ChoKIs). 
Moreover, choline kinase (ChoK) is an acknowledged drug target in eukaryotes (Lacal, 
2015) that exists in many species (Peisach et al., 2003). Several ChoKIs amounted to 
a surmountable inhibitory effect on the human choline kinase (hChoK) (Zimmerman 
and Ibrahim, 2017). It even demonstrated an effect on cancer (Janardhan et al., 2006; 
Lacal, 2008; Arlauckas et al., 2016) where hChoK is overexpressed (Glunde et al., 
2005; Krishnamachary et al., 2009; Granata et al., 2014), parasites such as Plasmodium 
falciparum (Zimmerman et al., 2013; Serrán-Aguilera et al., 2016), and autoimmune 
diseases (Guma et al., 2015). In prokaryotes, many pathogens possess a putative ChoK 
gene, such as S. aureus, Bacillus subtilis, Clostridium perfringens, and Clostridium 
botulinum (Zimmerman and Ibrahim, 2017). S. pneumoniae also has demonstrated a 
confirmed ChoK activity (Wang et al., 2015) and inhibition by ChoKIs (Zimmerman 





1.2.1 General objective:  
This study aims to produce pGEX plasmid constructs of S. aureus, H. 
influenzae, and N. meningitidis putative choline kinases for overexpression as GST-
tag recombinant proteins. This study also aims to use in silico approach to predict the 
heterologous protein expression, protein solubility, protein structure, and protein-
protein interactions to guide the overexpression of these proteins in E. coli and to 
model the structure of one of the bacterial choline kinases for molecular docking with 
a potential choline kinase inhibitor. 
1.2.2 Special objectives: 
• To produce pGEX plasmid constructs of S. aureus, H. influenzae, and 
N. meningitidis putative choline kinases  
• To predict the heterologous periplasmic protein expression, protein 
solubility, protein-protein interactions, and protein structure of the 
respective bacterial putative choline kinases. 
• To perform molecular docking of the putative choline kinase model 
structures of S. aureus, H. influenzae, and N. meningitidis with HC-3 
and subsequently perform tertiary structure protein alignment i.e. 
protein superimposition with the human choline kinase. 
1.3 The rationale of the study: 
To test out different ChoKIs to see their effect on the ChoK of different species 
of antibiotic-resistant bacteria, we first need to produce the ChoK recombinant protein 
of these bacteria in vitro. Specifically, S. aureus, H. influenzae, and N. meningitidis. 
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This way S. aureus ChoK (SaChoK), H. influenzae ChoK (HiChoK), and N. 
meningitidis ChoK (NmChoK) would serve as a readymade drug target for the 
investigation of ChoKIs effectiveness. Therefore, expression, purification, and 
characterization of putative choline kinases from these bacteria are paramount to 
further demonstrate the promising growth inhibition activity of the ChoKIs. The first 
step towards ending the menace of the AMR is producing a novel drug target i.e. 
ChoK, in the form of a recombinant protein standing by for testing. 
The discovery of new protocols for the production of an active and stable 
recombinant protein is paramount (Penning and Jez, 2001; Brannigan and Wilkinson, 
2002) for a better understanding of selectivity and function of the protein to inhibitors 
(Antikainen and Martin, 2005). To achieve that, high yields of the protein must be 
obtained in native form, which is difficult to do from natural sources, unlike the 
heterologous systems such as the commonly used E. coli system (Ferrer-Miralles et 
al., 2015). As such, this study attempted to clarify and predict the correct system and 
protocols to use to obtain satisfactory amounts of the ChoK from these 
microorganisms. Therefore, several bioinformatic predictions were performed to 
ascertain the most probable outcome and the likely parameters to achieve it. 
After the purification and verification, comes the characterization of the 
protein. This is a vital process where not only the produced protein is confirmed by 
the enzymatic activity, but data is produced that can act as a reference when testing 
modulators on the protein. In this case, the inhibitors are supposed to lower the 
enzymatic activity below the normal control protein. This is where the enzymatic assay 
plays an important role in the validation of the inhibitor activity on the protein. 
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Molecular docking has been the centerpiece for drug discovery for decades 
(Pinzi and Rastelli, 2019; Torres et al., 2019). This study has conducted molecular 
docking to demonstrate the viability and vitality of the application of ChoKIs to 
suppress the growth of the bacteria in question. Therefore, the most vital 
bioinformatics tool in this study is molecular docking to realize the potential of the end 
goal of this research, which is the eradication of AMR. Model structures of ChoK of 










CHAPTER 2  
 
LITERATURE REVIEW 
2.1 Recombinant protein as “The backbone”:  
The expression of the protein in the heterologous systems in the form of the 
recombinant protein has opened wide a lot of avenues and applications for the 
researchers to exploit. This has made it easier to obtain an in-depth understanding of 
the molecular processes of living beings. It would not be an exaggeration to claim that 
recombinant proteins have become the backbone of the world of proteomics. 
That being said, many challenges faced by expression systems, especially the 
most preferred one, E. coli, serve as roadblocks that hinder or even halt the expression 
(Fakruddin et al., 2013; Kaur et al., 2018). The roadblocks that require optimization to 
overcome include, codon biasing, vector and organism choice, the temperature of 
culture, induction time, formation of the insoluble inclusion bodies, inducer 
concentration, recombinant protein size, media additives (Kaur et al., 2018), and size 
of the DNA insert (Rai and Padh, 2000). 
With all these limitations, E. coli is still the most used expression system. A 
vast range of advantages has made E. coli the first choice for expression e.g. E. coli 
permits a manipulation with simple equipment,  has the potential to produce unlimited 
amounts of the recombinant protein, economic choice (Fakruddin et al., 2013), the 
unparalleled density of cell culture (Shiloach and Fass, 2005), easy and rapid growth 
(Sezonov et al., 2007; Kaur et al., 2018), and simple media making in a readily 
available form (Pope and Kent, 1996). That is just the tip of the iceberg. All these 
factors have made E. coli being studied extensively, which resulted in the emergence 
of many strains fit for each specific function. The best example would be the E. coli 
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BL21 strain for protein expression that lacks proteases such as Lon (Gottesman, 1996) 
and OmpT (Grodberg and Dunn, 1988). Nowadays, the huge selection of the available 
strains has made it easier to tackle any hurdles the researchers might face to obtain an 
overexpression of the recombinant protein of interest and subsequent desired testing. 
2.2 Pros and Cons of E. coli as a host: 
Ever since the production of the heterologous insulin produced in E. coli that 
was first clinically deployed in 1982 (Crowl et al., 1985), E. coli has been the go-to 
host for recombinant protein expression. That would be due to the many advantages 
E. coli possess. For better or worse, however, many factors contribute to this choice 
may help or hinder obtaining the protein in satisfactory quantities including: 
2.2.1 The unique sequence of the gene: 
DNA is involved in the transcriptions and translation stages of the recombinant 
protein synthesis inside the E. coli host (Fakruddin et al., 2013).  
2.2.1(a) Transcription stage vital sequences: 
Those vital sequences involved in transcription include: 
2.2.1(a)(i) The promoter: 
The promoter consists of the −35 and the −10 box regions and the spacer region 
between them (Glick and Whitney, 1987; Fakruddin et al., 2013). The optimal 
promoter is composed of the consensus sequence produced by the alignment of several 
promoters and it contains a spacer of 17 nucleotides (Glick and Whitney, 1987). For 
higher yields, the sequence of interest should be immediately downstream of a strong 
promoter (Carrier et al., 1983). Regulation of this strong promoter is important to 
prevent the loss of the plasmid (Ringquist et al., 1992). One of the most popular 
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promoters is T7 promoter systems present in the pET vectors, most notably, lacUV5 
promoter (Rosano and Ceccarelli, 2014). 
2.2.1(a)(ii) The terminator sequence: 
This sequence is essential to allow the stoppage of the transcription and 
expression at a certain point and exists in two classes, factor-independent and factor-
dependent terminators (Stormo et al., 1982). 
2.2.1(a)(iii) The regulatory sequence: 
The regulatory sequence regulates the transcription via activation through the 
transcriptional activators class or inhibition via transcriptional repressors class that 
binds to the promoter or immediately downstream from it preventing the RNA 
polymerase binding to the promoter (Schumann and Ferreira, 2004). 
2.2.1(a)(iv) The RNA polymerase: 
The RNA polymerase is the engine driving the transcription. It consists of α, 
β, β′, ω, and σ components. σ being the crucial component that recognizes the promoter 
(Gruber and Gross, 2003). 
2.2.1(b) Translation stage vital sequences: 
Those vital sequences involved in translation that might hinder it is the 
sequence of the 5′ end of each mRNA (Fakruddin et al., 2013). The initiation region 
of the translation comprises of four sequences: i) the start codon, ii) the Shine-
Dalgarno sequence, (iii) the spacer region between those two sequences with a length 
of 4 to 8 nucleotides optimally, and iv) translational enhancers (Ringquist et al., 1992; 
Schumann and Ferreira, 2004). The translation initiation region is paramount for an 
efficient gene expression e.g. the omittance of the Shine-Dalgarno sequence or the start 
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codon, blocks access to the 30S ribosomal unit, which inhibits the translation (Ramesh 
et al., 1994). 
2.2.2 Vector choice and stability: 
The vector that inserts of choice has been introduced to it, is transformed into 
competent E. coli cells, and becomes the source of the foreign recombinant protein of 
interest (Fakruddin et al., 2013). Vectors are commonly composed of many 
components that define the stability such as (Rosano and Ceccarelli, 2014), replicons 
that contain the copy number that must be adequate and too high that does not burden 
the metabolic machinery (del Solar and Espinosa, 2000), promoters (Rosano and 
Ceccarelli, 2014), selection markers such as antibiotic resistance genes that are used 
to retard the growth of cells without the vector (Korpimaki et al., 2003), multiple 
cloning sites, and fusion protein/fusion protein removal strategies (Rosano and 
Ceccarelli, 2014). The stability of the vector is also influenced by many other factors 
including the genotype of the vector and host, the size and origin of the DNA of interest 
(Rai and Padh, 2000), Plasmid loss in the defective segregation at cell division (Ashby 
and Stacey, 1984) that is commonly solved with the addition of the appropriate 
antibodies (Pierce and Gutteridge, 1985), elevated metabolic energy requirement for 
vector maintenance (Aiba et al., 1982), and physiological parameters such as pH, 
medium constituents, and temperature (Rai and Padh, 2000). Therefore, the structure 
of vectors (Figure 2.1) plays an important role in the successful overexpression of the 









Figure 2.1 Structure of the most common expression vectors detailing the most 











The pET vectors being the most used are an appropriate choice for the 
expression of the recombinant protein due to the high selectivity of T7 RNA 
polymerase to the T7 promoter sequence, highly active RNA polymerase, and the high 
translation efficiency of the gene 10 5´ leader translation initiation region signals 
(Agilent, 2017). pET vectors express His-tagged protein that makes it easily purified 
with Ni-NTA affinity chromatography (Xue et al., 2012; Trigoso et al., 2016). pGEX 
vectors on the other hand, despite not being very common, are very proficient and can 
express proteins otherwise difficult; where it has many advantages including the 
possible expression of soluble proteins with easy and proper folding that are otherwise 
expressed as inclusion bodies, the ability to purify it with ease with anti-GST, and the 
simplicity of analyzing GST-tagged proteins with western blot (Rukmana and 
Yasmon, 2018). 
2.2.3 Affinity tags vs inclusion bodies: 
Affinity tags are also an important component of the vectors that contribute 
vastly to the stability of the vector and are vital for the purification of the recombinant 
protein in a soluble active form (Fakruddin et al., 2013; Rosano and Ceccarelli, 2014). 
The goal is to form a fused or chimeric protein with a small sequence of amino acids 
(Nilsson et al., 1997). The downside is that there is a small possibility, it might have a 
negative impact on the tertiary structure or biological activity (Klose et al., 2004; 
Chant et al., 2005; Khan et al., 2012). The tag is preferably placed at the C-terminal 
to ensure the expression of the protein and in the solvent-accessible end (Rosano and 
Ceccarelli, 2014). The common peptide affinity tags used are the FLAG-, S-, poly-
His-, poly-Arg-, c-Myc-, and Strep II-tags (Terpe, 2003). In contrast, the common non-
peptide affinity tags that enhance solubility (Hammarström et al., 2002) with an 
unknown mechanism (Raran-Kurussi and Waugh, 2012) include glutathione S-
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transferase (GST) (Smith and Johnson, 1988), the maltose-binding protein (MBP) 
(Kapust and Waugh, 1999), N-utilization substance protein A (NusA) (Davis et al., 
1999), and ubiquitin (Baker, 1996). These solubility enhancers are highly efficient to 
the point that removing them will render the solubility of the protein of interest as 
unpredictable (Esposito and Chatterjee, 2006). On the other hand, if these tags are 
removed after expression, then the protein will attain the new higher solubility (Costa 
et al., 2013). 
2.2.4 The formation of the inclusion bodies: 
The formation of insoluble aggregates due to the rapid expression is known as 
inclusion bodies (Betts and King, 1999). These are large and spherical bodies that 
result from failure to remove the misfolded proteins (Blackwell and Horgan, 1991). 
The common practice, in this case, is to decrease the rate of expression by lowering 
the temperature, pH, copy number, and fusion with a solubilizing partner (Schumann 
and Ferreira, 2004). The fusion partners can also be used to increase the yield of 
expression by fusion with highly expressed fusion partner at the C-terminus (Sørensen 
and Mortensen, 2005) or to increase the detection by western blot via antibody-
recognizable peptide (Makrides, 1996). 
2.2.5 Manipulation of the location of the recombinant protein: 
The possibility to direct the recombinant protein to a specific location such as 
the cytoplasm, the inner or outer membrane, or the periplasmic space, has made it more 
advantageous to the manipulation of the expression of the recombinant protein 
(Baneyx, 1999). The expression of the protein in the periplasmic space allows for a 
higher yield due to the absence of proteases that might degrade the recombinant protein 
of interest (Hoffman and Wright, 1985). 
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2.2.6 Codon biasing: 
Imagine that 61 codons encode for 20 amino acids and with variable preference 
i.e. frequency that reflects the pool of tRNAs in the organism (Berg and Kurland, 
1997). The codons that have a large pool of tRNAs are used by highly expressed genes, 
while codons that have a small pool of tRNAs are used by the regulatory genes, 
however, the foreign gene expression is hinged on the availability of a specific tRNA 
(Stoletzki and Eyre-Walker, 2007). If the rare codons (least frequent) are 
overexpressed, it leads to the synthesis of a defective protein, even the location and 
amount of these rare codons can influence the translation and overall expression 
greatly e.g. rare codons near the promoter can stall the ribosome and halt the 
translations; however, this can be overcome by increasing the corresponding tRNAs 
or changing the rare codons with codons of high usage frequency (Chen and Inouye, 








Table 2.1 Arginine codon usage frequency in four species. Adapted from 
Fakruddin et al. (2013). 
Codon E. coli B.    subtilis S. cerevisiae Homo sapiens 
CGU 38 18 14 8 
CGC 40 21 6 19 
CGA 6 10 7 11 
CGG 10 16 4 22 
AGA 4 26 48 20 









2.3 Phosphatidylcholine vs Phosphorylcholine: 
The bacterial membranes are composed of many complex lipids, including 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidic acid (PA), phosphatidylglycerol (PG), phosphatidylinositol (PI),  
cardiolipin (CL), lysyl-phosphatidylglycerol (LPG), and glycolipids (GLs), 
(Sohlenkamp and Geiger, 2015). Gram-positive bacteria have a unique thick murein 
cell wall with an underlying cytoplasmatic membrane; Gram-negative bacteria, on the 
other hand, owns a sandwich-like structure of an outer, inner membrane, and a thin 
murein cell wall in between (Raetz and Whitfield, 2002; Silhavy et al., 2010; 
Reichmann and Grundling, 2011). Lipopolysaccharide (LPS) constitutes most of the 
outer membrane (Kamio and Nikaido, 1976; Raetz and Dowhan, 1990), especially, 
lipid A that constitutes the framework of the outer leaflet (Raetz et al., 2007) and 
mediates virulence (Rietschel et al., 1982). Besides being an essential component, lipid 
A is an established drug target in Gram-negative bacteria (Barb and Zhou, 2008; Zhou 
and Zhao, 2017; Wang et al., 2018). 
The infection magnitude and survival of S. pneumoniae hinge on the cell wall 
(Wang et al., 2015). Choline (Cho) is vital for cell wall integrity (Tomasz, 1967). The 
synthesis of phosphorylcholine (ChoP) from Cho is performed by ChoK (Whiting and 
Gillespie, 1996; Elswaifi et al., 2009). ChoP is necessary to produce teichoic acids 
(TA) in the form of cell wall teichoic acid (CTA) and lipoteichoic acid (LTA) adhered 
to the membrane, stipulating the essentiality of ChoP (Rane and Subbarow, 1940; 
Brundish and Baddiley, 1968; Mosser and Tomasz, 1970; Fischer and Tomasz, 1985; 
Skov Sorensen et al., 1988; Fischer, 1994; Whiting and Gillespie, 1996; Grundling and 
Schneewind, 2007; Seo et al., 2008; Denapaite et al., 2012; Gisch et al., 2013; Young 
et al., 2013). Remarkably, LTA and CTA have similar structures (Fischer et al., 1993). 
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Not only that, but ChoP also plays a role in the synthesis of type IV LTA of S. mitis 
and S. oralis (Fischer, 1997; Bergstrom et al., 2000; Seo et al., 2008; Denapaite et al., 
2012; Gisch et al., 2015). LTA mediates the development of AMR to Beta-lactams, 
which makes it a vital virulence factor and a potential drug target (Zhang et al., 1999; 
Ginsburg, 2002). 
LPS is essential for virulence (Zhang et al., 2013). LPS is related to the 
initiation of endotoxic shock, molding the protective barrier of the outer membrane 
(Raetz and Whitfield, 2002), and the host immune system sensitization (Silhavy et al., 
2010). The virulence is capitalized by the critical addition of ChoP to LPS and TA 
(Galán-Bartual et al., 2015), regardless of the rarity of this procedure (Young et al., 
2013). This modification of ChoP helps the survival of bacteria inside the host 
(Lysenko et al., 2000b; Mukherjee et al., 2011; Clark et al., 2012) and even nematodes 
(Harnett et al., 2010), aids in the host immunity recognition (Clark and Weiser, 2013) 
through C-reactive protein (CRP) (Volanakis and Kaplan, 1971), adhesion facilitation 
(Cundell et al., 1995; Weiser et al., 1997; Swords et al., 2000; Clark and Weiser, 2013), 
colonization (Lysenko et al., 2000b; Kharat and Tomasz, 2006; Clark et al., 2012), act 
as an adherence liaison to bacteriophage anchor and surface proteins ligands (Lopez 
and Garcia, 2004), and decrease genetic alteration and bacterial autolysis (Briese and 
Hakenbeck, 1985; Fischer, 2000). 
PC also plays an important role in many processes including the formation of 
the bilayer structure (Sohlenkamp et al., 2003), appropriate folding of the membrane 
protein (Bogdanov et al., 1996; Bogdanov et al., 1999), withstanding harsh 
environmental changes (Sohlenkamp et al., 2003), reducing susceptibility to 
antibiotics that impede with the bacterial membranes (Lysenko et al., 2000b), and is 
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paramount for the microbe-host interactions (Aktas et al., 2010; Joyce et al., 2019). As 
an example, when PC is diminished in several bacteria, it demonstrated reduced 
virulence such as Legionella (Conover et al., 2008), Brucella abortus (Comerci et al., 
2006), and Agrobacterium tumefaciens (Aktas et al., 2010; Aktas et al., 2014). In 
contrast, the virulence in P. aeruginosa did not undergo any change in virulence in the 
absence of PC (Malek et al., 2012). The selection of a novel drug target includes the 
consideration of the virulence factors (Maestro and Sanz, 2016). Therefore, ChoK 
would easily meet this requirement considering that ChoP and PC are like the building 
blocks of virulence. 
PC and PE are the most copious major lipids in eukaryotes (Nelson et al., 2008; 
Gibellini and Smith, 2010; Fagone and Jackowski, 2013; Vance and Tasseva, 2013). 
However, PC is estimated to be present in only 15% of bacteria (Geiger et al., 2013). 
In eukaryotes, both PC and PE are an essential component of the cell membrane and 
play an important role in various cellular functions (Farine et al., 2015). For example, 
PC degradation is essential for the production of secondary messengers i.e. the 
regulation of many cellular functions (Billah and Anthes, 1990). Therefore, any 
disruption in the PC pathway would hinder membrane movement (Fagone and 
Jackowski, 2013) and cell cycle (Northwood et al., 1999). 
2.4 Phosphatidylcholine and phosphorylcholine pathways: 
PE and PC synthesis in eukaryotes occurs mainly via the Kennedy pathway 
(Bakovic et al., 2007; Gibellini and Smith, 2010). PE is synthesized via the cytidine 
diphosphate-ethanolamine (CDP-ethanolamine) branch, while PC is synthesized via 
the cytidine diphosphate-choline (CDP-choline) branch (Kennedy and Weiss, 1956). 
However, PE can also be synthesized by decarboxylating PS (Vance, 2008) and base-
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exchange reactions with PS that also occur with PC (Sundler et al., 1974; Vance, 
2008). PC is also synthesized by PE methylation (Bremer et al., 1960; Bremer and 
Greenberg, 1961). Additionally, PE and PC are also obtained via acylation of 
lysophospholipids (LPLs) (Stein and Stein, 1966; Homma and Nojima, 1982). 
CDP-ethanolamine branch of the Kennedy pathway is initiated by 
phosphorylation of ethanolamine to ethanolamine-phosphate by ethanolamine kinase 
(EK) utilizing ATP, then CDP-ethanolamine is produced by ethanolamine-phosphate 
cytidylyltransferase (ECT) (Kennedy and Weiss, 1956; Sundler and Akesson, 1975; 
Gibellini and Smith, 2010; Farine et al., 2015). CDP-choline branch uses choline in 
similar reactions to produce CDP-choline (Gibellini and Smith, 2010). Finally, PE and 
PC are synthesized by ethanolamine, choline, and choline/ethanolamine 
phosphotransferases (EPT, CPT, and CEPT, respectively) (Gibellini and Smith, 2010; 
Farine et al., 2015). This last step of the CDP-choline pathway that produces PC is 
specifically catalyzed by 1,2-diacylglycerol choline phosphotransferase i.e. CPT 
utilizing diacylglycerol (DAG) in eukaryotes and CPT homologous in Treponema 
such as Treponema denticola, perhaps, not in any other prokaryotes (Vences-Guzmán 
et al., 2017). The study is needed here where it could be catalyzed by an enzyme in the 
bacteria other than Treponema. 
2.4.1 ChoP and PC prokaryotic pathways: 
ChoK is involved with the CDP-choline branch of the Kennedy pathway, 
which is present in bacteria as well (Sohlenkamp et al., 2003; Geiger et al., 2013; 
Sohlenkamp and Geiger, 2015; Joyce et al., 2019). This ChoP pathway is maintained 
by the uptake of Cho outside the cell via the choline transporter (LicB) (Fan et al., 
2001; Fan et al., 2003; Denapaite et al., 2012; Young et al., 2013). Cho is then 
phosphorylated using adenosine triphosphate (ATP) to ChoP by ChoK (LicA) in the 
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cytoplasm (Whiting and Gillespie, 1996; Eberhardt et al., 2009; Elswaifi et al., 2009; 
Sohlenkamp and Geiger, 2015; Zimmerman and Ibrahim, 2017; Zimmerman et al., 
2019). Therefore, LicA is critical for the ChoP pathway (Serino and Virji, 2002). 
Afterward, in the cytoplasm by phosphorylcholine cytidylyltransferase (CCT or LicC) 
utilizing cytidine triphosphate (CTP), ChoP is transformed into CDP-choline (Kwak 
et al., 2002; Zimmerman and Ibrahim, 2017; Zimmerman et al., 2019). to synthesize 
TA, Chop molecule is transferred from CDP-choline by phosphorylcholine 
transferases (LicD), particularly LicD1 and LicD2 in S. pneumoniae (LicD in H. 
influenzae transfers ChoP to LPS) to pre-teichoic acid produced by cytidylyl 
transferase (TarI) and alcohol dehydrogenase (TarJ) (Zhang et al., 1999; Lysenko et 
al., 2000a; Sohlenkamp et al., 2003; Baur et al., 2009; Denapaite et al., 2012; Geiger 
et al., 2013; Waldow et al., 2018). Finally, teichoic acid flippase (TacF) integrates TA 
into the cell wall and membrane (Damjanovic et al., 2007; Zimmerman and Ibrahim, 
2017; Zimmerman et al., 2019). This pathway (Figure 2.2) presents an opportunity to 
















Figure 2.2 Phosphorylcholine pathway in bacteria and CDP-choline pathway of 
phosphatidylcholine synthesis. The genes encoding for the responsible enzymes are 
in orange and substrates are in blue. Abbreviations not in the text: ADP, Adenosine 
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PC synthesis articulate in three other pathways too (Figure 2.3A-C) (Geiger et 
al., 2013; Sohlenkamp and Geiger, 2015; Joyce et al., 2019). The PE methylation 
pathway (Figure 2.3A) (Kaneshiro and Law, 1964; Sohlenkamp et al., 2003; 
Sohlenkamp and Geiger, 2015), where phospholipid N-methyltransferase (PLMT) 
catalyzing the methyl donor S-adenosylmethionine (SAM) to synthesize 
monomethylphosphatidylethanolamine (MMPE), dimethylphosphatidylethanolamine 
(DMPE), then PC from PE (Kaneshiro and Law, 1964; Arondel et al., 1993; de Rudder 
et al., 2000; Keogh et al., 2009; Sohlenkamp and Geiger, 2015). In some bacteria such 
as X. campestris, however, MMPE is the last product (Goldfine and Ellis, 1964; 
Tornabene, 1973; Moser et al., 2014). PE is synthesized in two steps, first from the 
collusion of CDP-DAG and serine by phosphatidylserine synthase (PSS) to form PS, 
which phosphatidylserine decarboxylase (PSD)  decarboxylates it to PE (DeChavigny 
et al., 1991; Sohlenkamp and Geiger, 2015). The PC synthase (Pcs) pathway (Figure 
2.3B) (de Rudder et al., 1999; Sohlenkamp et al., 2000), consists of the Pcs enzyme 
condensation of CDP-DAG with Cho (de Rudder et al., 1999; Sohlenkamp et al., 2000; 
Sohlenkamp and Geiger, 2015). The Glycerophosphocholine (GPC) pathway (Figure 
2.3C) (Moser et al., 2014; Sohlenkamp and Geiger, 2015; Joyce et al., 2019) was 
reported only in, S. mitis, S. oralis (Joyce et al., 2019), Xanthomonas campestris 
(Moser et al., 2014), and Saccharomyces cerevisiae (Stalberg et al., 2008). Here, 
extracellular GPC (Fisher et al., 2005) is transported and then transformed to 
lysophosphatidylcholine (LPC) then to PC via two acyl‐CoA‐dependent acylations by 
unknown enzymes except by X. campestris acyltransferases Xc_0188 and Xc_0238 for 
PC (Moser et al., 2014). The first acylation enzyme was identified in yeast as GPC 
acyltransferase (GPCAT) (Stalberg et al., 2008; Głąb et al., 2016), but not resolved in 
bacteria (Rottig and Steinbuchel, 2013; Moser et al., 2014; Joyce et al., 2019). 
